Clear Water from Pharmaceuticals – CWPharma

Environment Institute (Finland), County administrative board (Sweden), Environmental Research Centre (Estonia), Berlin Center for Competence of Water (Germany), Aarhus University (Denmark), Kalundborg Utility (Denmark), Technical facility Linköping (Sweden), Medicines Agency (Finland), Helsinki Region Environmental Services Authority (Finland), Institute of Environmental Protection - National Research Institute (Poland), Institute for Aquatic Ecology (Latvia), Environment, Geology, and Meteorology Centre (Latvia), Waterworks Association (Estonia), Association for Water, Wastewater, and Waste (Germany), and Environment Agency (Germany)

2017-2020

Baltic Sea Region

1) To give tools and recommendations to policy makers, authorities and municipalities on the best ways to reduce emissions of active pharmaceutical ingredients (APIs) in the Baltic Sea Region, 2) To fill the gaps of knowledge identified in, e.g. the status report of UNESCO and HELCOM on pharmaceuticals in the Baltic Sea (2017), 3) To increase the awareness of policy-makers, regulators and permitting authorities on environmental risks, implementation of the emission reduction schemes, and eventually decreasing the emissions of APIs into the Baltic Sea Region environment.

Environmental experts, Health Professionals, Hospitals/health system stakeholders, Local governments, National/Local decision and policy makers, Patients, Scientists, Staff of wastewater treatment plants, Waste/water treatment providers, and Water/waste service providers

Occurrence of pharmaceuticals in the environment, Pharmaceutical consumption by humans, Pharmaceutical waste & waste management, Prescription practices, Risks to ecosystems, Risks to human health, Unused/expired pharmaceutical disposal practices, Wastewater, and Water treatment technologies

1) Screening of a wide range of APIs in six river basin districts to get a more complete picture of sources, emissions and environmental concentrations of APIs, 2) Assessment of the overall emissions of APIs and their impact on the environment in the BSR based on the data from case studies and literature, 3) Evaluation of different emission reduction measures: advanced municipal wastewater treatment, improved take-back schemes and disposal for unused medicines, dissemination of environmental data on pharmaceutical products, and environmental permitting of pharmaceutical plants, 4) Promotion of the best existing practices of the partner countries.

• Clear Water from Pharmaceuticals – CWPharma
• Clear waters from pharmaceuticals – CWPharma: work package 2
• CWPharma – project in a nutshell
• CWPharma: Clear waters from pharmaceuticals
• PAC retention by Mecana pile cloth filter – Work Package 3
• PAC retention by microsieve – Work Package 3
• Concentration dependent degradation of pharmaceuticals in WWTP effluent by biofilm reactors
• Presence and risks of drugs in the Vantaanjoki watershed
• Pharmaceuticals in the Baltic Sea Region – emissions, consumption and environmental risks
• Evaluation and experiences of full-scale ozonation followed by MBBR post-treatment and comparison with previous pilot tests. CWPharma project report for GoA3.1: Pharmaceutical removal at full scale
• Impact of ozonation and post-treatment on ecotoxicological endpoints, water quality, APIs and transformation products. CWPharma project report for GoA3.3: Comparison of post-treatment options
• Guideline for advanced API removal. CWPharma project report for GoA3.4: Optimisation and control of advanced treatment
• Good practices for take-back and disposal of unused pharmaceuticals in the Baltic Sea region. Clear Waters from Pharmaceuticals (CWPharma) Activity 4.1 Report
• Recommendations for efficient dissemination of environmental information regarding pharmaceuticals Clear Waters from Pharmaceuticals (CWPharma) Activity 4.2 Report
• Enhanced environmental permitting of pharmaceutical plants in the Baltic Sea region. CWPharma project report for GoA4.3